-+ 0.00%
-+ 0.00%
-+ 0.00%
GrOwnValve Achieves Primary Safety Endpoint in First-in-Human Heart Valve Study
Share
Listen to the news

All five patients complete six-month follow-up without predefined prosthesis-related safety events

BERLIN, Oct. 26, 2026 /PRNewswire/ -- GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, today announced the achievement of the primary safety endpoint in the initial five-patient cohort of its GECT-DZHK28 first-in-human clinical study at the German Heart Center of Charité (DHZC).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending